Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending August 2011. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding the US Retirement Savings Plan.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory disclosure of a specific personnel transaction rather than a financial performance report.
Material Changes
No material changes to financial performance or operations are reported. The filing details a specific increase in the notional allocation of Ordinary share ADRs within the US Retirement Savings Plan due to a re-valuation of the cash element.
Guidance, Outlook, and Risks
The filing contains no management commentary, guidance, outlook, or discussion of risks and contingencies. It strictly reports a transaction notified in accordance with Disclosure and Transparency Rule 3.1.4R(1)(c).
Important Facts for Investors
- Transaction Date: The notional allocation increase occurred on August 5, 2011.
- Price: The transaction price was $41.82 per ADR.
- Parties Involved: The transaction involved Director Dr. M. M. Slaoui and Connected Person Dr. K. Slaoui.
- Volume: The transaction involved 5 ADRs.
- Context: This was a re-valuation event within a retirement plan, not a direct market purchase or sale by the individuals.